Laparoendoscopic single-site surgery in urologic patients: What does the future hold?
In this article, we briefly review the literature suggesting LESS is safe and holds a potential advantage over conventional laparoscopy. We then describe our techniques and outcomes for performing an extirpative (nephrectomy) and reconstructive (pyeloplasty) LESS procedure.
Review of the current literature
Since these initial reports with modest patient numbers, large, multi-institutional, multinational investigations have demonstrated LESS surgery to be safe with low complication rates (Eur Urol 2011; 60:998-1005; J Urol 2012; 187:1989-94). LESS surgery does not appear to place patients at additional risk compared to conventional laparoscopic operations. Further, there may be a marginal benefit with respect to in-hospital and early postoperative convalescence. The limited benefit of LESS surgery over conventional laparoscopy can be explained by one or more of the following factors:
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
